1. Poland Stocks

  2. •

    Health technology

  3. •

    Biotechnology
MultiQure S.A.

MultiQure S.A.

0.40
EUR
0.00
(0.00%)
7.19MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.02
0.78
3.46
0.5
0.15
0.05
0.13
- -
- -
- -
- -
Basic EPS, GAAP
-0.34
-0.33
-0.25
-1.17
-3.03
-2.26
-4.84
-4.76
-2.37
-1.99
- -
Free Cash Flow per Basic Share
-0.56
-2.26
-0.9
1.85
-0.49
-4.74
-4.37
-3.11
-1.32
-1.27
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.11
0.08
0.81
1.32
-0.74
7.46
3.46
0.24
-1.49
-1.25
-1.34
Tangible Book Value per Share
-0.03
-0.02
0.75
1.16
-1.01
7.32
3.38
0.21
-1.5
-1.25
-1.34
Basic Weighted Avg Shares
1
1
3
4
4
5
5
7
8
5
9
Sales/Revenue/Turnover
1
1
10
2
1
- -
1
- -
- -
- -
- -
Operating Margin (%)
-32.54
-39.34
-6.62
-217.91
-2,020.28
-4,128.74
-3,728.25
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
2
3
3
2
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-1
-4
-12
-12
-26
-36
-19
-10
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-33.59
-42.04
-7.23
-236.2
-2,055.24
-4,631.89
-3,867.52
- -
- -
- -
- -
Working Capital
- -
- -
2
3
-5
37
11
14
-13
-14
-16
LT Debt
- -
- -
- -
3
4
2
2
13
- -
- -
- -
Total Equity
- -
- -
2
5
-3
39
18
2
-13
-14
-16
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-158.29
-56.72
-114.32
- -
- -
-88.62
-353.58
- -
- -
- -

Capital Structure

PLN

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
15
16
16
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
11
12
Market Capitalization
38
34
31

Working Capital

PLN

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1
5
2
Cash, Cash Equivalents & STI
- -
- -
1
Accounts Receivable, Net
1
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
21
19
18
Payables & Accruals
- -
- -
- -
ST Debt
15
16
16
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-479.21%
7.86%
Free Cash Flow
- -
217.87%
-42.3%
Net Income, GAAP
- -
12.42%
-49.47%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.64
-0.38
-0.1
-1.22
-2.37
2025
-0.14
- -
-0.21
-0.31
-1.99
2026
-0.19
- -
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Filip Jan Jelen
Full Time Employees
7
Sector
Health technology
Industry
Biotechnology
Address
Wroclaw Poland
IPO Date
Dec 11, 2018
Website
purebiologics.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
MultiQure S.A. is a biotechnology company that discovers and develops biological drugs and RNA interference (RNAi) gene therapies for severe neurodegenerative conditions, rare genetic diseases, and oncological disorders. The company focuses on developing disease-modifying treatments through proprietary drug discovery platforms and advanced genetic therapeutic pipelines, providing a specialized portfolio that includes allele-selective RNAi gene therapies engineered to silence mutant huntingtin (HTT) transcripts while preserving wild-type expression for Huntington's disease and other polyglutamine repeat disorders; monoclonal antibodies and multi-specific fusion proteins for targeted immuno-oncology applications; anti-ROR1 therapeutic antibodies designed to induce antibody-dependent cellular cytotoxicity against solid and hematological tumors; and dual-mechanism biologics targeting immunosuppressive pathways, including the GARP-TGFβ1 complex, to reactivate antitumor immune responses. Founded in 2010 and headquartered in Wrocław, Poland, MultiQure conducts its scientific research and clinical development in Poland while targeting global biopharmaceutical markets through clinical collaborations and out-licensing partnerships. In recent corporate developments, the company executed a strategic business model transformation, officially changing its corporate name from Pure Biologics S.A. to MultiQure S.A. to reflect its core focus on genetic medicines. As part of this transition, the company integrated the multiQure RNAi platform through a multi-stage transaction involving Dystrogen Gene Therapies Inc., supported by a strategic partnership and equity investment from Biofund Capital Management, which acquired a major shareholding and secured PLN 50 million in capital to accelerate clinical development toward regulatory filings. Furthermore, MultiQure streamlined its internal operations and oncology assets by entering into a commercial transaction to transfer the global development rights of its lead immuno-oncology molecules, PBA-0405 (PB004) and PBA-0111 (PB003G), to US-based Promittens Corporation.